Welcome to Paid Research Studies




  • Conditions:   Aldosterone Disorder;   Adrenal Gland Disease;   Blood Pressure
    Interventions:   Dietary Supplement: Sodium loaded diet;   Dietary Supplement: Restricted sodium diet;   Drug: Angiotensin II;   Drug: Para-Aminohippurate
    Sponsors:   Brigham and Women's Hospital;   National Institutes of Health (NIH)
    Not yet recruiting

  • Conditions:   Adrenal Adenoma;   Cushing Syndrome;   Pheochromocytoma;   Adrenal Incidentaloma;   Adrenocortical Carcinoma;   Primary Hyperaldosteronism
    Intervention:   Other: Hormone study and Imaging study
    Sponsor:   Seoul National University Hospital
    Not yet recruiting

  • Condition:   Diagnosis of Primary Aldosteronism
    Intervention:   Other: no intervention
    Sponsor:   Chongqing Medical University
    Recruiting

  • Condition:   Adrenal Tumor
    Intervention:  
    Sponsor:   University Hospital, Brest
    Not yet recruiting

  • Condition:   Primary Aldosteronism Due to Aldosterone Producing Adenoma
    Interventions:   Procedure: AVS performed with no intraprocedural rapid cortisol assay;   Procedure: AVS performed plus intraprocedural rapid cortisol assay
    Sponsor:   University Hospital Padova
    Not yet recruiting

  • Condition:   Adrenal Insufficiency
    Intervention:   Other: Patient education
    Sponsors:   Wuerzburg University Hospital;   Medical University of Graz, Austria;   Medical practice for Endocrinology in Oldenburg, Germany;   Charite University, Berlin, Germany;   University Hospital, Frankfurt, Germany;   Endocrinology in Charlottenburg, Berlin, Germany;   University Hospital Munich, Germany;   University Hospital of Rostock, Germany
    Recruiting

  • Condition:   Hyperaldosteronism
    Intervention:   Drug: Clarithromycin
    Sponsors:   University Hospital Padova;   DMG Paris Descartes
    Not yet recruiting

  • Conditions:   Primary Aldosteronism;   Hypertension
    Intervention:   Procedure: Endovascular chemical Ablation of Adrenal Gland
    Sponsor:   Third Military Medical University
    Recruiting

  • Conditions:   Primary Hyperaldosteronism;   Primary Hyperaldosteronism Due to Adrenal Adenoma
    Interventions:   Procedure: Endoscopic ultrasound guided radiofrequency ablation;   Device: ultrasound
    Sponsors:   University College, London;   Queen Mary University of London;   British Heart Foundation;   University of Cambridge;   Cambridge University Hospitals NHS Foundation Trust;   Barts & The London NHS Trust;   University College London Hospitals
    Not yet recruiting

  • Conditions:   Hypercortisolism;   Cushing Syndrome
    Intervention:  
    Sponsor:   Corcept Therapeutics
    Recruiting

  • Conditions:   Adrenal Gland Neoplasm;   Hypertension;   Bone Diseases, Metabolic;   Cardiovascular Disease;   Hyperinsulinemia
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Condition:   Adrenocortical Carcinoma
    Intervention:   Drug: Cabozantinib
    Sponsors:   M.D. Anderson Cancer Center;   Exelixis
    Recruiting

  • Conditions:   Adrenal Insufficiency;   Cirrhosis;   Spur Cell Anemia;   Lecithin Acyltransferase Deficiency
    Intervention:   Drug: Cosyntropin
    Sponsor:   University of Virginia
    Recruiting

  • Conditions:   Sickle Cell Disease;   Thalassemia;   High Risk Hematologic Disorders;   Cerebral Adrenoleukodystrophy;   Inherited Metabolic Disorders
    Intervention:   Procedure: Blood and Marrow Transplant
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting

  • Conditions:   Cushing's Disease;   Cushing Syndrome;   Cushing Disease
    Interventions:   Other: Cushing's QoL (Quality of Life Questionnaire);   Other: Nottingham Health Profile (NHP);   Other: Hospital Anxiety and Depression Scale (HADS);   Other: Perceived Stress Scale (PSS);   Other: Barratt's Impulsivity Scale (BIS);   Other: Beck Depression Inventory (BDI);   Other: State-Trait Anxiety Inventory (STAI);   Other: State Food Craving Questionnaire-State (FCQ-S);   Other: Trait Food Craving Questionnaire-Trait (FCQ-T);   Other: Visual Analogue Scale (VAS);   Other: Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Cushing Syndrome
    Intervention:  
    Sponsors:   University of Roma La Sapienza;   Federico II University;   University of Palermo;   University of Florence;   Ospedali Riuniti Ancona;   University of Padova
    Recruiting

  • Condition:   Adrenal Insufficiency
    Interventions:   Drug: Infacort;   Drug: Cortef
    Sponsors:   Diurnal Limited;   Simbec Research;   Brush Clinical Research Ltd.;   Voet Consulting;   EMAS Pharma;   Medical Matters International Ltd.
    Not yet recruiting

  • Conditions:   Genitourinary Cancer;   Adrenocortical Carcinoma;   Non-urothelial Bladder;   Non-urothelial Upper Tract;   Penile Cancer;   Non-adenocarcinoma Prostate Cancer;   Refractory Germ-cell
    Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Rheumatoid Arthritis;   Adrenal Insufficiency
    Intervention:  
    Sponsor:   University of Edinburgh
    Not yet recruiting

  • Condition:   Endogenous Cushing's Syndrome
    Interventions:   Drug: Levoketoconazole;   Drug: Placebo
    Sponsor:   Cortendo AB
    Recruiting

  • Condition:   X-Linked Adrenoleukodystrophy
    Intervention:  
    Sponsor:   NeuroVia, Inc.
    Recruiting

  • Conditions:   Congenital Adrenal Hyperplasia;   CAH - Congenital Adrenal Hyperplasia
    Intervention:   Drug: SPR001
    Sponsor:   Spruce Biosciences
    Recruiting

  • Condition:   Adrenocortical Carcinoma
    Intervention:   Drug: Cabazitaxel
    Sponsors:   Azienda Ospedaliera Spedali Civili di Brescia;   San Luigi Gonzaga Hospital
    Recruiting

  • Condition:   Primary Aldosteronism
    Intervention:   Other: no intervention
    Sponsor:   Chongqing Medical University
    Recruiting

  • Condition:   Adrenoleukodystrophy
    Interventions:   Drug: MIN-102;   Drug: Placebos
    Sponsor:   Minoryx Therapeutics, S.L.
    Not yet recruiting

  • Condition:   Addison Disease
    Intervention:   Drug: Dexamethasone
    Sponsor:   Göteborg University
    Not yet recruiting

  • Condition:   Cushing Syndrome
    Intervention:  
    Sponsors:   Göteborg University;   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau;   Leiden University Medical Center
    Recruiting

  • Condition:   Primary Aldosteronism
    Intervention:   Drug: Everolimus 0.75 mg
    Sponsor:   University Hospital, Basel, Switzerland
    Recruiting

  • Condition:   X-Linked Adrenoleukodystrophy
    Intervention:   Drug: Sobetirome (NV1205)
    Sponsor:   NeuroVia, Inc.
    Not yet recruiting

  • Conditions:   Primary Aldosteronism;   Primary Aldosteronism Due to Aldosterone Producing Adenoma;   Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
    Interventions:   Procedure: Adrenalectomy;   Drug: Mineralocorticoid Receptor Antagonists
    Sponsor:   Changi General Hospital
    Recruiting

  • Condition:   Adrenal Insufficiency
    Intervention:  
    Sponsors:   Chronic Obstructive Pulmonary Disease Trial Network, Denmark;   Rigshospitalet, Denmark
    Recruiting

  • Condition:   Adrenal Insufficiency
    Intervention:   Diagnostic Test: Synacthen test
    Sponsor:   Rigshospitalet, Denmark
    Recruiting

  • Conditions:   Hyperaldosteronism; Primary;   Hypertension Secondary
    Interventions:   Diagnostic Test: Aldosterone/renin ratio (ARR) testing;   Diagnostic Test: Confirmatory tests
    Sponsors:   Qifu Li;   Fu Wai Hospital, Beijing, China
    Recruiting

  • Condition:   Congenital Adrenal Hyperplasia
    Intervention:   Other: Collection of growth and bone maturation data
    Sponsor:   Hospices Civils de Lyon
    Recruiting

  • Conditions:   Osteoporosis in Cushing's Syndrome;   Osteoporosis in Post-menopausal Women
    Intervention:   Other: Osteodensitometry and pQCT
    Sponsors:   University Hospital, Clermont-Ferrand;   Unité de recherche GReD CNRS UMR6293 / Inserm
    Recruiting

  • Conditions:   Adrenocortical Carcinoma;   Peritoneal Carcinomatosis
    Interventions:   Drug: Cisplatin;   Drug: Sodium thiosulfate;   Procedure: Cytoreductive surgery
    Sponsor:   Columbia University
    Recruiting

  • Conditions:   Primary Aldosteronism;   Hypertension;   Hypertension Secondary
    Intervention:  
    Sponsors:   Uppsala University;   Uppsala-Örebro Regional Research Council
    Recruiting

  • Condition:   Iatrogenic Cushing's Disease
    Interventions:   Drug: AZD4017 and prednisolone;   Drug: Placebo Oral Tablet and prednisolone
    Sponsors:   University of Oxford;   AstraZeneca
    Recruiting

  • Condition:   Endocrine Disease
    Interventions:   Other: Data Collection;   Behavioral: Follow Up
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Adrenal Insufficiency;   Adrenal Cancer
    Intervention:   Diagnostic Test: Cosyntropin stimulation test
    Sponsor:   Bnai Zion Medical Center
    Recruiting

  • Condition:   Cushing Syndrome
    Interventions:   Drug: ATR-101;   Drug: Placebos
    Sponsor:   Millendo Therapeutics, Inc.
    Recruiting

  • Condition:   Congenital Adrenal Hyperplasia
    Intervention:   Drug: Hydrocortisone
    Sponsor:   Diurnal Limited
    Recruiting

  • Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Partial Mineralocorticoid Deficiency
    Interventions:   Drug: Oral Fludrocortisone (enteral);   Drug: Placebo Oral Tablet
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Recruiting

  • Condition:   Adrenal Insufficiency Neonatal
    Intervention:   Other: No pre-operative steroids
    Sponsor:   University of Alabama at Birmingham
    Recruiting

  • Conditions:   Primary Aldosteronism;   Hyperaldosteronism
    Intervention:   Procedure: adrenalectomy
    Sponsors:   Queen Mary University of London;   National Institute for Health Research, United Kingdom;   WBIC), Cambridge. University of Cambridge Addenbrookes Hospital, Cambridge CB2 2QQ;   Robertson Centre for Biostatistics University of Glasgow Glasgow G12 8QQ;   Barts and the London School of Medicine and Dentistry W Smithfield London - City of London EC1A 7BE
    Recruiting

  • Condition:   Adrenoleukodystrophy
    Intervention:  
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting

  • Condition:   Apparent Mineralocorticoid Excess
    Intervention:   Dietary Supplement: Liquorice
    Sponsor:   The Royal Wolverhampton Hospitals NHS Trust
    Recruiting

  • Conditions:   Adrenal Insufficiency;   Congenital Adrenal Hyperplasia;   Cushing Syndrome;   Growth Hormone Deficiency;   Acromegaly;   Primary Hyperaldosteronism
    Intervention:   Other: 27 hour subcutaneous fluid sampling
    Sponsors:   Haukeland University Hospital;   Karolinska Institutet;   University Hospitals Bristol NHS Foundation Trust;   Evaggelismos Hospital, Greece
    Recruiting

  • Condition:   Cushing's Syndrome
    Intervention:  
    Sponsor:   Corcept Therapeutics
    Recruiting

  • Conditions:   Adrenal Cortex Carcinoma;   Adult Alveolar Soft Part Sarcoma;   Adult Clear Cell Sarcoma of Soft Parts;   Adult Hepatocellular Carcinoma;   Adult Rhabdomyosarcoma;   Adult Soft Tissue Sarcoma;   Childhood Alveolar Soft Part Sarcoma;   Childhood Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Childhood Hepatocellular Carcinoma;   Childhood Rhabdomyosarcoma;   Childhood Soft Tissue Sarcoma;   Childhood Solid Neoplasm;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Hepatocellular Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Refractory Osteosarcoma;   Renal Cell Carcinoma;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hyperaldosteronism
    Intervention:  
    Sponsor:   Haukeland University Hospital
    Recruiting

  • Condition:   Adrenal Insufficiency
    Intervention:   Drug: Synachten
    Sponsor:   Haukeland University Hospital
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastrointestinal Stromal Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Cushing's Syndrome
    Intervention:   Drug: CORT125134
    Sponsor:   Corcept Therapeutics
    Recruiting

  • Conditions:   Adrenal Insufficiency;   Growth Disorder;   Endocrine Diseases;   Metabolic Disease;   Bone Diseases, Metabolic
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Primary Aldosteronism;   Adrenal Adenoma
    Intervention:   Device: Radiofrequency ablation
    Sponsor:   University Hospital, Toulouse
    Recruiting

  • Conditions:   Sleep Apnea;   Arrhythmias, Cardiac;   Cardiac Diastolic Function;   Hyperaldosteronism
    Interventions:   Other: pacemaker diagnostic algorithm;   Other: Attended cardiorespiratory sleep study
    Sponsors:   University Hospital, Caen;   LivaNova
    Recruiting

  • Condition:   Congenital Adrenal Hyperplasia
    Interventions:   Drug: Chronocort®;   Drug: standard glucocorticoid therapy
    Sponsor:   Diurnal Limited
    Recruiting

  • Condition:   Adrenocortical Carcinoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Cushings Syndrome
    Intervention:   Other: Children refered to the obesity clinic
    Sponsor:   Haukeland University Hospital
    Recruiting

  • Conditions:   Advanced Solid Tumors (Part A/B/C/D);   Non-small Cell Lung Cancer (Part E);   Melanoma (Part E);   Squamous Cell Cancer of the Head and Neck (Part E);   Triple Negative Breast Cancer (Part F);   Adrenocortical Carcinoma (Part G);   Mesothelioma (Part G)
    Interventions:   Drug: IPI-549;   Drug: Nivolumab
    Sponsor:   Infinity Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Cushing's Syndrome Cardiomyopathy
    Intervention:   Drug: Tadalafil
    Sponsor:   Andrea M. Isidori
    Recruiting

  • Condition:   Congenital Adrenal Hyperplasia
    Intervention:   Drug: Abiraterone acetate
    Sponsors:   University of Texas Southwestern Medical Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   University of Michigan;   Children's Hospital Los Angeles;   Feinstein Institute for Medical Research
    Recruiting

  • Conditions:   Cushing's Syndrome;   Ectopic Corticotropin Syndrome;   Adrenal Adenoma;   Adrenal Carcinoma;   AIMAH;   PPNAD
    Intervention:   Drug: Osilodrostat
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Adrenal Incidentalomas
    Interventions:   Procedure: Laparoscopic surgical removal of the adrenal tumor;   Drug: Standardized medical treatment of hypertension by SAHR
    Sponsor:   University Hospital, Bordeaux
    Recruiting

  • Condition:   Primary Aldosteronism
    Interventions:   Other: Adrenalectomy;   Drug: mineralocorticoid receptor antagonist
    Sponsors:   Vanderbilt University;   Brigham and Women's Hospital;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Hypercortisolism
    Interventions:   Biological: Blood samples for measuring adiponectin, leptin and omentin plasma;   Device: MRI at 3 Tesla
    Sponsor:   Assistance Publique Hopitaux De Marseille
    Recruiting

  • Conditions:   Adrenal Incidentaloma;   Adrenocortical Carcinoma
    Intervention:  
    Sponsors:   University Medical Center Groningen;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   VU University Medical Center;   Radboud University;   Leiden University Medical Center;   Maastricht University Medical Center;   UMC Utrecht;   Erasmus Medical Center;   Martini Hospital Groningen;   Canisius-Wilhelmina Hospital;   Diakonessenhuis, Utrecht;   Isala;   Haga Hospital;   St. Antonius Hospital;   Kennemer Gasthuis;   Maxima Medical Center;   Medical Center Alkmaar;   Medical Centre Leeuwarden;   Meander Medical Center;   Medisch Spectrum Twente;   Onze Lieve Vrouwe Gasthuis;   Rijnstate Hospital;   Elisabeth-TweeSteden Ziekenhuis;   Tergooi Hospital;   Vlietland Ziekenhuis;   Scheper Hospital;   Flevo Hospital
    Recruiting

  • Conditions:   Adrenoleukodystrophy;   Batten Disease;   Mucopolysaccharidosis II;   Leukodystrophy, Globoid Cell;   Leukodystrophy, Metachromatic;   Neimann Pick Disease;   Pelizaeus-Merzbacher Disease;   Sandhoff Disease;   Tay-Sachs Disease;   Brain Diseases, Metabolic, Inborn;   Alpha-Mannosidosis;   Sanfilippo Mucopolysaccharidoses
    Intervention:   Biological: DUOC-01
    Sponsors:   Joanne Kurtzberg, MD;   The Marcus Foundation
    Recruiting

  • Conditions:   X-Linked Adrenoleukodystrophy (X-ALD);   Cerebral Adrenoleukodystrophy (CALD);   Adrenoleukodystrophy (ALD)
    Intervention:   Genetic: Allo-HSCT
    Sponsor:   bluebird bio
    Recruiting

  • Conditions:   Mucopolysaccharidosis Disorders;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Alpha-Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Glycoprotein Metabolic Disorders;   Sphingolipidoses;   Recessive Leukodystrophies;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann-Pick B;   Niemann-Pick C Subtype 2;   Sphingomyelin Deficiency;   Peroxisomal Disorders;   Adrenoleukodystrophy With Cerebral Involvement;   Zellweger Syndrome;   Neonatal Adrenoleukodystrophy;   Infantile Refsum Disease;   Acyl-CoA Oxidase Deficiency;   D-Bifunctional Enzyme Deficiency;   Multifunctional Enzyme Deficiency;   Alpha-methylacyl-CoA Racmase Deficiency;   Mitochondrial Neurogastrointestingal Encephalopathy;   Severe Osteopetrosis;   Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation);   Inherited Metabolic Disorders
    Interventions:   Biological: Stem Cell Transplantation;   Drug: IMD Preparative Regimen;   Drug: Osteopetrosis Only Preparative Regimen;   Drug: Osteopetrosis Haploidentical Only Preparative Regimen;   Drug: cALD SR-A (Standard-Risk, Regimen A);   Drug: cALD SR-B (Standard-Risk, Regimen B);   Drug: cALD HR-D (High-Risk, Regimen C);   Drug: cALD HR-D (High-Risk, Regimen D)
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Cushing Syndrome
    Interventions:   Drug: F-DOPA PET Scan;   Drug: Mifepristone;   Drug: Ga-DOTATATE;   Drug: Octreoscan;   Other: CT, MRI
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Condition:   Adrenal Gland Neoplasms
    Interventions:   Other: FDG positron emission tomography;   Other: Iodometomidate imaging
    Sponsors:   Wuerzburg University Hospital;   Charite University, Berlin, Germany;   Heinrich-Heine University, Duesseldorf;   University Hospital, Essen;   Johannes Gutenberg University Mainz;   Ludwig-Maximilians - University of Munich;   Hannover Medical School;   University of Leipzig;   University of Florence;   University of Padova;   Cambridge University Hospitals NHS Foundation Trust;   University Medical Center Nijmegen;   Uppsala University Hospital;   Assistance Publique - Hôpitaux de Paris;   University of Vienna
    Recruiting

  • Condition:   Cerebral Adrenoleukodystrophy (CALD)
    Intervention:   Genetic: Lenti-D Drug Product
    Sponsor:   bluebird bio
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Conditions:   Alzheimer Disease;   Oxidative Stress;   Adrenocortical Hyperfunction
    Intervention:  
    Sponsor:   Raffaele Antonelli Incalzi
    Recruiting

  • Condition:   Adrenal Tumour With Mild Hypercortisolism
    Intervention:   Procedure: Adrenalectomy
    Sponsor:   Region Skane
    Recruiting

  • Conditions:   Endocrine Tumors;   Thyroid Neoplasms;   Parathyroid Neoplasms;   Adrenal Neoplasm;   Neuroblastoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Adrenocortical Carcinoma
    Intervention:   Drug: MITOTANE
    Sponsor:   University of Turin, Italy
    Recruiting

  • Condition:   Adrenocortical Tumor
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Adrenal Gland Neoplasm
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Adrenal Insufficiency;   Pituitary Neoplasm;   Obesity
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Cushing's Syndrome;   Hereditary Neoplastic Syndrome;   Lentigo;   Neoplasm;   Testicular Neoplasm
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Abnormalities;   Craniopharyngioma;   Cushing's Syndrome;   Endocrine Disease;   Pituitary Neoplasm
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Condition:   Cushing Syndrome
    Interventions:   Drug: Pentetreotide;   Drug: 18-F-fluorodeoxyglucose;   Drug: (18F)-L-3,4-dihydroxyophenylalanine (18F-DOPA)
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting